Alligator Bioscience AB (publ) Interim report January-June 2020
(WorldNews Sweden)

Alligator Bioscience AB (publ) Interim report January-June 2020 Promising safety data for ATOR-1015 `With the new strategy announced in early April, we have put a stronger focus on Alligator`s clinical development portfolio. ATOR-1015 has received a great deal of attention in connection with the positive interim data presented at AACR and ASCO, the world`s two largest oncology conferences. We have also worked actively with business development and signed a research agreement with Scandion Oncology during the period, while our collaboration with Biotheus developed well and led to an additional milestone payment. The Covid-19 pandemic has been stressful but has not led to any serious delays in...